Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

NCT02323880 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02323880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02323880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
October 30, 2015
Completion date
December 31, 2024
Enrollment
59 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

malignant glioma, recurrent brain neoplasm, recurrent childhood central nervous system neoplasm, recurrent childhood glioblastoma, recurrent lymphoma, recurrent malignant solid neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory primary central nervous system neoplasm, who grade 3 glioma